대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	The Sarcopenic Obesity Paradigm in CKD
저자	Csaba Kovesdy
출판정보	2024; 2024(1):
키워드
초록	There are ~600 million people worldwide affected by obesity. Obesity is an important risk factor for CKD; yet once patients develop CKD, a large proportion suffers from malnutrition (also called protein-energy wasting, PEW). One of the characteristics of PEW is the presence of sarcopenia, defined as the presence of low muscle mass along low muscle strength. Sarcopenic obesity is a condition where low lean body mass (sarcopenia) is accompanied by the presence of increased fact mass, especially visceral fat mass. The prevalence of sarcopenic obesity increases with advancing age. The mechanisms of sarcopenic obesity are complex and include a humoral factors (some of which are age-related) and lifestyle factors. CKD is a condition predisposing to sarcopenic obesity, due to the enhanced presence of several of these mechanisms. The prevalence of sarcopenic obesity increases in those with more severe stages of CKD, and it can be as high as 20% in patients with stage 4 CKD. Sarcopenia and sarcopenic obesity is associated with increased mortality both in patients with CKD and in those with normal kidney function. Interventions targeting sarcopenic obesity should focus primarily on increasing muscle mass, and include various exercise regimens and the administration of anabolic medications (e.g., human growth hormone, anabolic steroids, etc.). These interventions can successfully increase muscle mass, but their impact on clinical outcomes remains unclear. The impact interventions targeting adiposity in patients with advanced CKD and ESRD are controversial and require further studies.
원문(PDF)	PDF 원문보기

목록

위로가기